{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:45:59Z","timestamp":1792269959265,"version":"4.4.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T00:00:00Z","timestamp":1481932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s40265-016-0670-4","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T12:43:26Z","timestamp":1481978606000},"page":"29-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Current Pharmacological Approaches to Reduce Chorea in Huntington\u2019s Disease"],"prefix":"10.1007","volume":"77","author":[{"given":"Emma M.","family":"Coppen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund A. C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,17]]},"reference":[{"key":"670_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis."},{"key":"670_CR2","doi-asserted-by":"publisher","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev. 2009;(3):CD006456. doi: 10.1002\/14651858.CD006456.pub2 .","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"670_CR3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","volume":"29","author":"J Jankovic","year":"2014","unstructured":"Jankovic J, Roos RAC. Chorea associated with Huntington\u2019s disease: to treat or not to treat? Mov Disord. 2014;29:1414\u20138.","journal-title":"Mov Disord"},{"key":"670_CR4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"670_CR5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","volume":"47","author":"S Monte De la","year":"1988","unstructured":"De la Monte S, Vonsattel J, Richardson E. Morphometric demonstration of atrophic changes in cerebral cortex, white matter and neostriatum in Huntington\u2019s disease. J Neuropathol Exp Neurol. 1988;47:516\u201325.","journal-title":"J Neuropathol Exp Neurol"},{"key":"670_CR6","doi-asserted-by":"crossref","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol. 1985;44:559\u201377.","DOI":"10.1097\/00005072-198511000-00003"},{"key":"670_CR7","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD, D\u2019Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 1988;85:5733\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"670_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369\u201384.","journal-title":"J Neuropathol Exp Neurol"},{"key":"670_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S. Treatment of Huntington\u2019s disease. Neurotherapeutics. 2014;11:153\u201360.","journal-title":"Neurotherapeutics."},{"key":"670_CR10","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1260.","journal-title":"PLoS Curr"},{"key":"670_CR11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","volume":"23","author":"J Priller","year":"2008","unstructured":"Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington\u2019s disease. Mov Disord. 2008;23:1788.","journal-title":"Mov Disord"},{"key":"670_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2015.00177","volume":"6","author":"L Wojtecki","year":"2015","unstructured":"Wojtecki L, Groiss S, Ferrea S, Elben S, Hartmann C, Dunnett S, et al. A prospective pilot trial for pallidal deep brain stimulation in Huntington\u2019s disease. Front Neurol. 2015;6:1\u201311.","journal-title":"Front Neurol."},{"key":"670_CR13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","volume":"85","author":"E Duijn van","year":"2014","unstructured":"van Duijn E, Craufurd D, Hubers AAM, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85:1411\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"670_CR14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mds.24024","volume":"27","author":"A Rosenblatt","year":"2012","unstructured":"Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA. Age, CAG repeat length, and clinical progression in Huntington\u2019s disease. Mov Disord. 2012;27:272\u20136.","journal-title":"Mov Disord"},{"key":"670_CR15","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/mds.25997","volume":"29","author":"JS Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD. Onset of Huntington\u2019s disease: can it be purely cognitive? Mov Disord. 2014;29:1342\u201350.","journal-title":"Mov Disord"},{"key":"670_CR16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11:474\u201383.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"670_CR17","first-page":"25","volume-title":"Huntington\u2019s dis.","author":"RAC Roos","year":"2014","unstructured":"Roos RAC. Clinical neurology. In: Bates G, Tabrizi S, Jones L, editors. Huntington\u2019s dis. 4th ed. Oxford: Oxford University Press; 2014. p. 25\u201335.","edition":"4"},{"key":"670_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VSC, et al. Phenomenology and classification of dystonia : a consensus update. Mov Disord. 2013;28:863\u201373.","journal-title":"Mov Disord"},{"key":"670_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996;11:136\u201342.","journal-title":"Mov Disord"},{"key":"670_CR20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/mds.26012","volume":"29","author":"CA Ross","year":"2014","unstructured":"Ross CA, Pantelyat A, Kogan J, Brandt J. Determinants of functional disability in Huntington\u2019s disease: role of cognitive and motor dysfunction. Mov Disord. 2014;29:1351\u20138.","journal-title":"Mov Disord"},{"key":"670_CR21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.22003","volume":"23","author":"YMA Grimbergen","year":"2008","unstructured":"Grimbergen YMA, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M. Falls and gait disturbances in Huntington\u2019s disease. Mov Disord. 2008;23:970\u20136.","journal-title":"Mov Disord"},{"key":"670_CR22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/01.WNL.0000052992.58107.67","volume":"60","author":"VL Wheelock","year":"2003","unstructured":"Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60:998\u20131001.","journal-title":"Neurology."},{"key":"670_CR23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mds.22412","volume":"24","author":"AK Ho","year":"2009","unstructured":"Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington\u2019s disease: which factors matter most? Mov Disord. 2009;24:574\u20138.","journal-title":"Mov Disord"},{"key":"670_CR24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mds.1056","volume":"16","author":"DI Helder","year":"2001","unstructured":"Helder DI, Kaptein AA, van Kempen GMJ, van Houwelingen JC, Roos RAC. Impact of Huntington\u2019s disease on quality of life. Mov Disord. 2001;16:325\u201330.","journal-title":"Mov Disord"},{"key":"670_CR25","first-page":"1","volume":"1","author":"M Orth","year":"2010","unstructured":"Orth M, Handley O, Schwenke C, Dunnett S, Craufurd D, Ho A, et al. Observing Huntington\u2019s disease: the European Huntington\u2019s disease Network\u2019s REGISTRY. PLoS Curr. 2010;1:1\u201317.","journal-title":"PLoS Curr."},{"key":"670_CR26","first-page":"218","volume-title":"Huntington\u2019s dis.","author":"MS Levine","year":"2014","unstructured":"Levine MS, Wang EA, Chen JY, Cepeda C, Andre VM. Altered neuronal circuitry. In: Bates G, Tabrizi SJ, Jones L, editors. Huntington\u2019s dis. 4th ed. Oxford: Oxford University Press; 2014. p. 218\u201340.","edition":"4"},{"key":"670_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","volume":"16","author":"VM Andr\u00e9","year":"2010","unstructured":"Andr\u00e9 VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington\u2019s disease: a balancing act. CNS Neurosci Ther. 2010;16:163\u201378.","journal-title":"CNS Neurosci Ther"},{"key":"670_CR28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14737175.2015.1025383","volume":"15","author":"LC Schwab","year":"2015","unstructured":"Schwab LC, Garas SN, Drouin-Ouellet J, Mason SL, Stott SR, Barker RA. Dopamine and Huntington\u2019s disease. Expert Rev Neurother. 2015;15:445\u201358.","journal-title":"Expert Rev Neurother"},{"key":"670_CR29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"J-M Beaulieu","year":"2011","unstructured":"Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182\u2013217.","journal-title":"Pharmacol Rev"},{"key":"670_CR30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","volume":"43","author":"G Pagano","year":"2016","unstructured":"Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43:1171\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"670_CR31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","volume":"126","author":"N Pavese","year":"2003","unstructured":"Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study. Brain. 2003;126:1127\u201335.","journal-title":"Brain."},{"key":"670_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","volume":"120","author":"N Ginovart","year":"1997","unstructured":"Ginovart N, Lundin A, Farde L, Halldin C, B\u00e4ckman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease. Brain. 1997;120:503\u201314.","journal-title":"Brain."},{"key":"670_CR33","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington\u2019s disease progression. PET and clinical observations. Brain. 1999;122:2353\u201363.","journal-title":"Brain."},{"key":"670_CR34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","volume":"14","author":"JB Carroll","year":"2015","unstructured":"Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington \u2019 s disease. Lancet Neurol. 2015;14:1135\u201342.","journal-title":"Lancet Neurol"},{"key":"670_CR35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487\u2013504 (Elsevier Inc.).","journal-title":"Clin Ther."},{"key":"670_CR36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1073\/pnas.80.2.584","volume":"80","author":"D Scherman","year":"1983","unstructured":"Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci USA. 1983;80:584\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"key":"670_CR37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","volume":"8","author":"DRP Guay","year":"2010","unstructured":"Guay DRP. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331\u201373 (Excerpta Medica Inc.).","journal-title":"Am J Geriatr Pharmacother."},{"key":"670_CR38","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Clarence-smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509\u201323.","journal-title":"Expert Rev Neurother"},{"key":"670_CR39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366\u201372.","journal-title":"Neurology."},{"key":"670_CR40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol. 2009;9:62.","journal-title":"BMC Neurol."},{"key":"670_CR41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358\u201362.","journal-title":"Neurology."},{"key":"670_CR42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","volume":"25","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington\u2019s disease-associated chorea. Clin Neuropharmacol. 2002;25:300\u20132.","journal-title":"Clin Neuropharmacol"},{"key":"670_CR43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington\u2019s disease. Mov Disord. 2007;22:10\u20133.","journal-title":"Mov Disord"},{"key":"670_CR44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","volume":"31","author":"A Fasano","year":"2008","unstructured":"Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31:313\u20138.","journal-title":"Clin Neuropharmacol"},{"key":"670_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1756285612471700","volume":"6","author":"J-M Burgunder","year":"2013","unstructured":"Burgunder J-M. Recent advances in the management of choreas. Ther Adv Neurol Disord. 2013;6:117\u201327.","journal-title":"Ther Adv Neurol Disord."},{"key":"670_CR46","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"R Reilmann","year":"2013","unstructured":"Reilmann R. Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28:1030\u20133.","journal-title":"Mov Disord"},{"key":"670_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","volume":"27","author":"CS Venuto","year":"2012","unstructured":"Venuto CS, Mcgarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington\u2019s disease. Mov Disord. 2012;27:31\u201341.","journal-title":"Mov Disord"},{"key":"670_CR48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/11534430-000000000-00000","volume":"70","author":"S Frank","year":"2010","unstructured":"Frank S, Jankovic J. Advances in the pharmacological management of Huntingtons disease. Drugs. 2010;70:561\u201371.","journal-title":"Drugs."},{"key":"670_CR49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79:597\u2013603.","journal-title":"Neurology."},{"key":"670_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2000-7964","volume":"33","author":"M Dose","year":"2000","unstructured":"Dose M, Lange HW. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry. 2000;33:19\u201327.","journal-title":"Pharmacopsychiatry."},{"key":"670_CR51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","volume":"65","author":"RA Roos","year":"1982","unstructured":"Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde E. Tiapride in the treatment of Huntington\u2019s chorea. Acta Neurol Scand. 1982;65:45\u201350.","journal-title":"Acta Neurol Scand"},{"key":"670_CR52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","volume":"9","author":"J Deroover","year":"1984","unstructured":"Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington\u2019s chorea. Curr Med Res Opin. 1984;9:329\u201338.","journal-title":"Curr Med Res Opin"},{"key":"670_CR53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","volume":"15","author":"MM Iqbal","year":"2003","unstructured":"Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33\u201348.","journal-title":"Ann Clin Psychiatry"},{"key":"670_CR54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.136.3.317","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136:317\u201320.","journal-title":"Am J Psychiatry"},{"key":"670_CR55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","volume":"44","author":"U Bonuccelli","year":"1994","unstructured":"Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington\u2019s chorea. Neurology. 1994;44:821\u20133.","journal-title":"Neurology."},{"key":"670_CR56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","volume":"63","author":"JP Vugt van","year":"1997","unstructured":"van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63:35\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"670_CR57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","volume":"21","author":"G Bogelman","year":"2001","unstructured":"Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington\u2019s disease. J Clin Psychopharmacol. 2001;21:245.","journal-title":"J Clin Psychopharmacol"},{"key":"670_CR58","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163\u201391.","journal-title":"EXCLI J."},{"key":"670_CR59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","volume":"15","author":"A Videnovic","year":"2013","unstructured":"Videnovic A. Treatment of huntington disease. Curr Treat Options Neurol. 2013;15:424\u201338.","journal-title":"Curr Treat Options Neurol."},{"key":"670_CR60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","volume":"67","author":"H Dipple","year":"1999","unstructured":"Dipple H. The use of olanzapine for movement disorder in Huntington\u2019s disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67:123\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"670_CR61","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69\u201372.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"key":"670_CR62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","volume":"25","author":"R Bonelli","year":"2002","unstructured":"Bonelli R, Mahnert F, Niederwieser G. Olanzapine for Huntington\u2019s disease: an open label study. Clin Neuropharmacol. 2002;25:263\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"670_CR63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","volume":"105","author":"D Paleacu","year":"2002","unstructured":"Paleacu D, Anca M, Giladi N. Olanzapine in Huntington\u2019s disease. Acta Neurol Scand. 2002;105:441\u20134.","journal-title":"Acta Neurol Scand"},{"key":"670_CR64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1345\/aph.17216","volume":"33","author":"CS Brown","year":"1999","unstructured":"Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II. Adverse effects, drug interactions, and costs. Ann Pharmacother. 1999;33:210\u20137.","journal-title":"Ann Pharmacother"},{"key":"670_CR65","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626.","DOI":"10.1002\/14651858.CD006626.pub2"},{"key":"670_CR66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/026988119601000213","volume":"10","author":"MA Reveley","year":"1996","unstructured":"Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington\u2019s disease: a pilot study. J Psychopharmacol. 1996;10:162\u20135.","journal-title":"J Psychopharmacol."},{"key":"670_CR67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington Chorea patients. J Clin Psychopharmacol. 1999;19:101\u20133.","journal-title":"J Clin Psychopharmacol"},{"key":"670_CR68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","volume":"9","author":"AK Erdemoglu","year":"2002","unstructured":"Erdemoglu AK, Boratov C. Risperidone in chorea and psychosis of Huntington\u2019s disease. Eur J Neurol. 2002;9:182\u20133.","journal-title":"Eur J Neurol"},{"key":"670_CR69","first-page":"1353","volume":"98","author":"ES Cankurtaran","year":"2006","unstructured":"Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease. J Natl Med Assoc. 2006;98:1353\u20135.","journal-title":"J Natl Med Assoc"},{"key":"670_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, Beglinger LJ, O\u2019Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry. 2008;20:1\u20133.","journal-title":"Ann Clin Psychiatry"},{"key":"670_CR71","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/070674370404900617","volume":"49","author":"D Seitz","year":"2004","unstructured":"Seitz D, Millson R. Quetiapine in the management of psychosis secondary to Huntington\u2019s disease: a case report. Can J Psychiatry. 2004;49:413.","journal-title":"Can J Psychiatry"},{"key":"670_CR72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","volume":"47","author":"M Alpay","year":"2006","unstructured":"Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington\u2019s disease. Psychosomatics. 2006;47:70\u20132.","journal-title":"Psychosomatics."},{"key":"670_CR73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","volume":"249","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G. Quetiapine in Huntington\u2019s disease: a first case report. J Neurol. 2002;249:1114\u20135.","journal-title":"J Neurol"},{"key":"670_CR74","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/mds.10024","volume":"17","author":"CG Goetz","year":"2002","unstructured":"Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C, Brin MF, et al. Amantadine and other antiglutamate agents. Mov Disord. 2002;17:S13\u201322.","journal-title":"Mov Disord"},{"key":"670_CR75","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"L Verhagen","year":"2002","unstructured":"Verhagen L, Morris M, Farmer C, Gillespie M, Mosby K, Wuu J, et al. Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59:694\u20139.","journal-title":"Neurology."},{"key":"670_CR76","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O\u2019Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60:996\u20138.","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"670_CR77","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s100720200081","volume":"23","author":"C Lucetti","year":"2002","unstructured":"Lucetti C, Gambaccini G, Bernardini S, Dell\u2019Agnello G, Petrozzi L, Rossi G, et al. Amantadine in Huntington\u2019s disease: open-label video-blinded study. Neurol Sci. 2002;23(Suppl 2):S83\u20134.","journal-title":"Neurol Sci."},{"key":"670_CR78","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","volume":"348","author":"J Wokke","year":"1996","unstructured":"Wokke J. Riluzole. Lancet. 1996;348:795\u20139.","journal-title":"Lancet."},{"key":"670_CR79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","volume":"14","author":"HD Rosas","year":"1999","unstructured":"Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, et al. Riluzole therapy in Huntington\u2019s disease (HD). Mov Disord. 1999;14:326\u201330.","journal-title":"Mov Disord"},{"key":"670_CR80","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","volume":"248","author":"K Seppi","year":"2001","unstructured":"Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, et al. Riluzole in Huntington\u2019s disease (HD): an open label study with one year follow up. J Neurol. 2001;248:866\u20139.","journal-title":"J Neurol"},{"key":"670_CR81","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","volume":"61","author":"Group HS","year":"2003","unstructured":"Huntington Study Group. Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study. Neurology. 2003;61:1551\u20136.","journal-title":"Neurology."},{"key":"670_CR82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"GB Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, Dubois B, De Yebenes JG, Kremer B, Gaus W, Kraus PH, et al. Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62:262\u201372.","journal-title":"Ann Neurol."},{"key":"670_CR83","doi-asserted-by":"publisher","unstructured":"Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447. doi: 10.1002\/14651858.CD001447.pub3 .","DOI":"10.1002\/14651858.CD001447.pub3"},{"key":"670_CR84","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s40265-014-0231-7","volume":"74","author":"M Shirley","year":"2014","unstructured":"Shirley M, Perry CM. Aripiprazole (Abilify maintena): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74:1097\u2013110.","journal-title":"Drugs."},{"key":"670_CR85","first-page":"1","volume":"5","author":"A Ciammola","year":"2009","unstructured":"Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, et al. Aripiprazole in the treatment of Huntington\u2019s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1\u20134.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"670_CR86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington\u2019s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24:126\u20139.","journal-title":"Mov Disord"},{"key":"670_CR87","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.23402","volume":"26","author":"MS Pena","year":"2011","unstructured":"Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26:147\u201352.","journal-title":"Mov Disord"},{"key":"670_CR88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5694\/j.1326-5377.1976.tb140550.x","volume":"1","author":"J Peiris","year":"1976","unstructured":"Peiris J, Boralessa H, Lionel N. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225\u20137.","journal-title":"Med J Aust"},{"key":"670_CR89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00007611-198801000-00029","volume":"81","author":"J Stewart","year":"1988","unstructured":"Stewart J. Treatment of Huntington\u2019s disease with clonazepam. South Med J. 1988;81:102.","journal-title":"South Med J"},{"key":"670_CR90","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","volume":"35","author":"WC Koller","year":"1985","unstructured":"Koller WC, Trimble J. The gait abnormality of Huntington\u2019s disease. Neurology. 1985;35:1450\u20134.","journal-title":"Neurology."},{"key":"670_CR91","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","volume":"47","author":"F Girotti","year":"1984","unstructured":"Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 1984;47:848\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"670_CR92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.38.1.84","volume":"38","author":"AN Barr","year":"1988","unstructured":"Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington\u2019s disease. Neurology. 1988;38:84\u20138.","journal-title":"Neurology."},{"key":"670_CR93","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","volume":"47","author":"N Quinn","year":"1984","unstructured":"Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington\u2019s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1984;47:844\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"670_CR94","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","volume":"28","author":"M Tommaso de","year":"2005","unstructured":"de Tommaso M, di Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro MF, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"670_CR95","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/mds.21061","volume":"21","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington\u2019s disease. Mov Disord. 2006;21:1998\u20132001.","journal-title":"Mov Disord"},{"key":"670_CR96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2009.334","volume":"67","author":"K Kieburtz","year":"2010","unstructured":"Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010;67:154\u201360.","journal-title":"Arch Neurol"},{"key":"670_CR97","first-page":"1582","volume":"65","author":"Huntington Study Group","year":"2008","unstructured":"Huntington Study Group. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65:1582\u20139.","journal-title":"Arch Neurol"},{"key":"670_CR98","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord. 2009;24:2254\u20139.","journal-title":"Mov Disord"},{"key":"670_CR99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","volume":"30","author":"R Reilmann","year":"2015","unstructured":"Reilmann R, Rouzade-Dominguez M, Saft C, Sussmuth S, Priller J, Rosser A, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease. Mov Disord. 2015;30:427\u201331.","journal-title":"Mov Disord"},{"key":"670_CR100","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"J Lopez-Sendon Moreno","year":"2016","unstructured":"Lopez-Sendon Moreno J, Caldentey J, Cubillo P, Ruiz Romero C, Ribas G, Arias M, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol. 2016;263:1390\u2013400.","journal-title":"J Neurol"},{"key":"670_CR101","doi-asserted-by":"crossref","first-page":"P07.210","DOI":"10.1212\/WNL.80.7_supplement.P07.210","volume":"80","author":"D Stamler","year":"2013","unstructured":"Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology. 2013;80:P07.210.","journal-title":"Neurology"},{"key":"670_CR102","volume-title":"Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the First-HD and Tetra-HD trials","author":"D Claassen","year":"2016","unstructured":"Claassen D, Carroll B, de Boer L, Wu E, Ayyagari R, Gandhi S, et al. Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the First-HD and Tetra-HD trials. Germany: Int Congr Park Dis Mov Disord Berlin; 2016."},{"key":"670_CR103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.0970","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40\u201350.","journal-title":"JAMA"},{"key":"670_CR104","unstructured":"Sung V, Stamler D, Claassen D. Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): updated week 8 results for the switch cohort [abstract]. Mov Disord. 2016;31."},{"key":"670_CR105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","volume":"628","author":"T Dyhring","year":"2010","unstructured":"Dyhring T, Nielsen E, Sonesson C, Pettersson F, Karlsson J, Svensson P, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010;628:19\u201326.","journal-title":"Eur J Pharmacol"},{"key":"670_CR106","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","volume":"644","author":"H Ponten","year":"2010","unstructured":"Ponten H, Kullingsj\u00f6 J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010;644:88\u201395.","journal-title":"Eur J Pharmacol"},{"key":"670_CR107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","volume":"33","author":"A Lundin","year":"2010","unstructured":"Lundin A, Dietrichs E, Haghighi S, G\u00f6ller M-L, Heiberg A, Loutfi G, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington\u2019s disease. Clin Neuropharmacol. 2010;33:260\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"670_CR108","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Huntington Study Group HART Investigators","year":"2013","unstructured":"Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28:1407\u201315.","journal-title":"Mov Disord"},{"key":"670_CR109","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG Yebenes De","year":"2011","unstructured":"De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:1049\u201357.","journal-title":"Lancet Neurol"},{"key":"670_CR110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/13543784.2016.1153627","volume":"25","author":"KM Shannon","year":"2016","unstructured":"Shannon KM. Pridopidine for the treatment of Huntington\u2019s disease. Expert Opin Investig Drugs. 2016;25:485\u201392.","journal-title":"Expert Opin Investig Drugs"},{"key":"670_CR111","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.2147\/DDDT.S65738","volume":"9","author":"F Squitieri","year":"2015","unstructured":"Squitieri F, de Yebenes JG. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Des Devel Ther. 2015;9:5827\u201333.","journal-title":"Drug Des Devel Ther."},{"key":"670_CR112","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1007\/s00415-016-8233-x","volume":"263","author":"M Jacobs","year":"2016","unstructured":"Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, et al. Progression of motor subtypes in Huntington\u2019s disease: a 6-year follow-up study. J Neurol. 2016;263:2080\u20135.","journal-title":"J Neurol"},{"key":"670_CR113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","volume":"17","author":"SL Mason","year":"2016","unstructured":"Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntington\u2019s disease: a review of the existing literature. Expert Opin Pharmacother. 2016;17:41\u201352.","journal-title":"Expert Opin Pharmacother"},{"key":"670_CR114","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.23816","volume":"26","author":"R Reilmann","year":"2011","unstructured":"Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington\u2019s disease-toward objective and quantitative measures. Mov Disord. 2011;26:2267\u201373.","journal-title":"Mov Disord"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0670-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0670-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0670-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T18:13:14Z","timestamp":1749838394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0670-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,17]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0670-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,17]]}}}